Pharmaceutical stocks are on roll with most of the frontline stocks trading higher in the range of 1-5% in otherwise weak market on the Bombay Stock Exchange (BSE).
Aurobindo Pharma, Wockhardt, Sun Pharmaceutical Industries, Ranbaxy Laboratories, Lupin and Dr Reddy’s Laboratories are up 1-5% on the BSE.
At 1230 hours, S&P BSE has surged 143 points or 1.2% compared to 0.83% or 200 points fall in benchmark index S&P BSE Sensex.
Aurobindo Pharma, the largest gainer among pharma pack, has rallied 5% to Rs 700 on back of heavy volumes. The stock opened at Rs 663 and hit a high of Rs 708 so far.
The overseas investors are continuously buying equity shares of Aurobindo Pharma from the open market. Foreign institutional investors (FIIs) holdings in pharmaceutical company touch almost seven-year high to 27.59% in June quarter.
FIIs held 23.74% stake in the company in March quarter, purchased an additional 3.85 percentage point stake in June quarter. They held 12.45% stake in the company at the end of September 2012 quarter.
FIIs also raised their holdings in Ranbaxy Laboratories, Biocon and Natco Pharma in June quarter, the shareholding pattern data shows.
Aurobindo Pharma, Wockhardt, Sun Pharmaceutical Industries, Ranbaxy Laboratories, Lupin and Dr Reddy’s Laboratories are up 1-5% on the BSE.
At 1230 hours, S&P BSE has surged 143 points or 1.2% compared to 0.83% or 200 points fall in benchmark index S&P BSE Sensex.
Aurobindo Pharma, the largest gainer among pharma pack, has rallied 5% to Rs 700 on back of heavy volumes. The stock opened at Rs 663 and hit a high of Rs 708 so far.
The overseas investors are continuously buying equity shares of Aurobindo Pharma from the open market. Foreign institutional investors (FIIs) holdings in pharmaceutical company touch almost seven-year high to 27.59% in June quarter.
FIIs held 23.74% stake in the company in March quarter, purchased an additional 3.85 percentage point stake in June quarter. They held 12.45% stake in the company at the end of September 2012 quarter.
FIIs also raised their holdings in Ranbaxy Laboratories, Biocon and Natco Pharma in June quarter, the shareholding pattern data shows.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%